Covered recipient · General Payments record
CARL R GRAY
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2025 · Entire year
$3,159.46
151 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2025 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $3,094.46 | 150 |
| Education | $65.00 | 1 |
By paying entity
PY2025 · entire year · sorted by reported total
Page 3 of 4; records 101–150 of 151 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
CARL R GRAY
NPI 1598873382 · CMS profile ID 949771
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
OGDEN, UT
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 4; records 101–150 of 151 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1598873382?year=2025&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- CARL R GRAY, NPI 1598873382, CMS profile ID 949771. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 151 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1598873382?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- APA 7
- IndustryPayments. (2026). CARL R GRAY, NPI 1598873382, CMS profile ID 949771. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 151 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1598873382?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- Bluebook
- CARL R GRAY, NPI 1598873382, CMS profile ID 949771, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 151 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1598873382?year=2025&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30
151 matching records · $3,159.46 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–150 of 151.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $20.93 | 04/24/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200211182 | CMS |
| Novartis Pharmaceuticals Corporation | $18.84 | 04/23/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200211184 | CMS |
| EMD Serono, Inc. | $23.93 | 04/22/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1236889956 | CMS |
| EMD Serono, Inc. | $14.18 | 04/21/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1236918562 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $24.08 | 04/15/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1225557374 | CMS |
| Novartis Pharmaceuticals Corporation | $18.55 | 04/14/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200211186 | CMS |
| Novartis Pharmaceuticals Corporation | $0.48 | 04/14/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200211188 | CMS |
| AstraZeneca Pharmaceuticals LP | $21.03 | 04/10/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206461761 | CMS |
| Novartis Pharmaceuticals Corporation | $30.98 | 04/09/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200211192 | CMS |
| Genentech USA, Inc. | $29.96 | 04/07/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1211500755 | CMS |
| SOBI, INC | $24.11 | 04/03/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1240262490 | CMS |
| Janssen Biotech, Inc. | $14.39 | 04/02/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1175191990 | CMS |
| ABBVIE INC. | $21.05 | 03/26/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1201957698 | CMS |
| Genmab U.S., Inc. | $18.89 | 03/26/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1235918696 | CMS |
| PUMA BIOTECHNOLOGY, INC. | $17.16 | 03/26/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1251742268 | CMS |
| E.R. Squibb & Sons, L.L.C. | $22.87 | 03/24/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1184864959 | CMS |
| PFIZER INC. | $15.18 | 03/21/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1231489834 | CMS |
| PFIZER INC. | $1.18 | 03/20/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1231414470 | CMS |
| Genentech USA, Inc. | $34.88 | 03/19/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1211500751 | CMS |
| PFIZER INC. | $16.20 | 03/18/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1231438521 | CMS |
| Deciphera Pharmaceuticals Inc. | $22.51 | 03/17/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1235959119 | CMS |
| Janssen Biotech, Inc. | $16.04 | 03/13/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1175192579 | CMS |
| ARRAY BIOPHARMA INC | $0.84 | 03/11/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1231446316 | CMS |
| ARRAY BIOPHARMA INC | $19.26 | 03/11/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1231473739 | CMS |
| AstraZeneca Pharmaceuticals LP | $29.15 | 03/06/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206169757 | CMS |
| AstraZeneca Pharmaceuticals LP | $17.09 | 03/05/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206669328 | CMS |
| Geron Corporation | $17.57 | 03/04/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238888940 | CMS |
| Novartis Pharmaceuticals Corporation | $16.16 | 02/24/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200211176 | CMS |
| SERVIER PHARMACEUTICALS LLC | $24.47 | 02/19/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1229093851 | CMS |
| Eisai Inc. | $18.14 | 02/18/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1244469984 | CMS |
| PFIZER INC. | $0.60 | 02/18/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1231265055 | CMS |
| PFIZER INC. | $11.68 | 02/18/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1231570493 | CMS |
| Novartis Pharmaceuticals Corporation | $24.25 | 02/17/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200211180 | CMS |
| GlaxoSmithKline, LLC. | $20.32 | 02/13/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1190397266 | CMS |
| E.R. Squibb & Sons, L.L.C. | $24.56 | 02/12/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1184864943 | CMS |
| Novartis Pharmaceuticals Corporation | $10.75 | 02/11/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200211178 | CMS |
| Daiichi Sankyo Inc. | $23.78 | 02/10/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1197040059 | CMS |
| Azurity Pharmaceuticals, Inc. | $24.64 | 02/06/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1242671694 | CMS |
| Genmab U.S., Inc. | $22.47 | 02/06/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1235918692 | CMS |
| Eisai Inc. | $20.41 | 02/04/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1244469980 | CMS |
| ARRAY BIOPHARMA INC | $16.08 | 02/03/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1231368924 | CMS |
| AstraZeneca Pharmaceuticals LP | $24.30 | 01/29/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1207035369 | CMS |
| Janssen Biotech, Inc. | $13.63 | 01/28/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1175192594 | CMS |
| Lilly USA, LLC | $21.97 | 01/22/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186542533 | CMS |
| EMD Serono, Inc. | $27.29 | 01/21/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1236874946 | CMS |
| AstraZeneca Pharmaceuticals LP | $20.86 | 01/20/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206996459 | CMS |
| Eisai Inc. | $20.20 | 01/14/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1244469978 | CMS |
| PharmaEssentia USA Corporation | $17.34 | 01/13/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1246830069 | CMS |
| Amneal Pharmaceuticals LLC | $15.85 | 01/09/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1220534983 | CMS |
| PharmaEssentia USA Corporation | $14.12 | 01/07/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1246830065 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $716.53 | 1 |
| PY2025 | Principal investigator | $607,409.33 | 67 |
| PY2024 | Recipient | $2,990.13 | 14 |
| PY2024 | Principal investigator | $657,485.79 | 74 |
| PY2023 | Principal investigator | $471,654.43 | 47 |
| PY2022 | Principal investigator | $162,386.93 | 28 |
| PY2021 | Principal investigator | $187,277.59 | 66 |
| PY2020 | Principal investigator | $115,914.46 | 45 |
| PY2019 | Principal investigator | $295,261.79 | 51 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
68 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Janssen Research & Development, LLC | $4,657.00 | 12/19/2025 | Non-covered Recipient Entity COMMUNITY CANCER TRIALS OF UTAH LLC | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1175415375 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,195.00 | 12/19/2025 | Non-covered Recipient Entity COMMUNITY CANCER TRIALS OF UTAH LLC | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1175415436 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $500.00 | 12/19/2025 | Non-covered Recipient Entity COMMUNITY CANCER TRIALS OF UTAH LLC | A PHASE 3, OPEN LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN COMBINATION WITH CHOP (O-CHOP) VERSUS RITUXIMAB IN COMBINATION WITH CHOP (R-CHOP) IN PREVIOUSLY UNTREATED PARTICIPANTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) (OLYMPIA-3) | No dispute reported | 06/30/2026 | 1184279024 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,000.00 | 12/19/2025 | Non-covered Recipient Entity COMMUNITY CANCER TRIALS OF UTAH LLC | A PHASE 3, OPEN LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN COMBINATION WITH CHOP (O-CHOP) VERSUS RITUXIMAB IN COMBINATION WITH CHOP (R-CHOP) IN PREVIOUSLY UNTREATED PARTICIPANTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) (OLYMPIA-3) | No dispute reported | 06/30/2026 | 1184279026 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,000.00 | 12/19/2025 | Non-covered Recipient Entity COMMUNITY CANCER TRIALS OF UTAH LLC | A PHASE 3, OPEN LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN COMBINATION WITH CHOP (O-CHOP) VERSUS RITUXIMAB IN COMBINATION WITH CHOP (R-CHOP) IN PREVIOUSLY UNTREATED PARTICIPANTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) (OLYMPIA-3) | No dispute reported | 06/30/2026 | 1184279028 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,000.00 | 12/19/2025 | Non-covered Recipient Entity COMMUNITY CANCER TRIALS OF UTAH LLC | A PHASE 3, OPEN LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN COMBINATION WITH CHOP (O-CHOP) VERSUS RITUXIMAB IN COMBINATION WITH CHOP (R-CHOP) IN PREVIOUSLY UNTREATED PARTICIPANTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) (OLYMPIA-3) | No dispute reported | 06/30/2026 | 1184279030 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,488.00 | 12/15/2025 | Non-covered Recipient Entity COMMUNITY CANCER TRIALS OF UTAH LLC | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1175415425 |
| Principal investigator 1 | ABBVIE INC. | $2,091.70 | 12/04/2025 | Non-covered Recipient Entity COMMUNITY CANCER TRIALS OF UTAH | A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1202526468 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $500.00 | 12/04/2025 | Non-covered Recipient Entity COMMUNITY CANCER TRIALS OF UTAH LLC | A PHASE 3, OPEN LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN COMBINATION WITH CHOP (O-CHOP) VERSUS RITUXIMAB IN COMBINATION WITH CHOP (R-CHOP) IN PREVIOUSLY UNTREATED PARTICIPANTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) (OLYMPIA-3) | No dispute reported | 06/30/2026 | 1184269197 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $67.88 | 11/19/2025 | Non-covered Recipient Entity Utah Hematology Oncology Ogden Clinic | Beamion LUNG-3: A randomized, controlled, multi-center trial evaluating zongertinib as an adjuvant monotherapy compared with standard of care in patients with early-stage, resectable non-small cell lung cancer (Stage II-IIIB) harboring tyrosine kinase domain activating HER2 mutations | No dispute reported | 06/30/2026 | 1220696153 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $23.32 | 11/19/2025 | Non-covered Recipient Entity Utah Hematology Oncology Ogden Clinic | Beamion LUNG-3: A randomized, controlled, multi-center trial evaluating zongertinib as an adjuvant monotherapy compared with standard of care in patients with early-stage, resectable non-small cell lung cancer (Stage II-IIIB) harboring tyrosine kinase domain activating HER2 mutations | No dispute reported | 06/30/2026 | 1220696155 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.96 | 11/19/2025 | Non-covered Recipient Entity Utah Hematology Oncology Ogden Clinic | Beamion LUNG-3: A randomized, controlled, multi-center trial evaluating zongertinib as an adjuvant monotherapy compared with standard of care in patients with early-stage, resectable non-small cell lung cancer (Stage II-IIIB) harboring tyrosine kinase domain activating HER2 mutations | No dispute reported | 06/30/2026 | 1220696157 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,227.60 | 11/19/2025 | Non-covered Recipient Entity Utah Hematology Oncology Ogden Clinic | Beamion LUNG-3: A randomized, controlled, multi-center trial evaluating zongertinib as an adjuvant monotherapy compared with standard of care in patients with early-stage, resectable non-small cell lung cancer (Stage II-IIIB) harboring tyrosine kinase domain activating HER2 mutations | No dispute reported | 06/30/2026 | 1220696159 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $9.28 | 11/19/2025 | Non-covered Recipient Entity Utah Hematology Oncology Ogden Clinic | Beamion LUNG-3: A randomized, controlled, multi-center trial evaluating zongertinib as an adjuvant monotherapy compared with standard of care in patients with early-stage, resectable non-small cell lung cancer (Stage II-IIIB) harboring tyrosine kinase domain activating HER2 mutations | No dispute reported | 06/30/2026 | 1220696161 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $285.60 | 11/19/2025 | Non-covered Recipient Entity Utah Hematology Oncology Ogden Clinic | Beamion LUNG-3: A randomized, controlled, multi-center trial evaluating zongertinib as an adjuvant monotherapy compared with standard of care in patients with early-stage, resectable non-small cell lung cancer (Stage II-IIIB) harboring tyrosine kinase domain activating HER2 mutations | No dispute reported | 06/30/2026 | 1220696163 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $31.62 | 11/19/2025 | Non-covered Recipient Entity Utah Hematology Oncology Ogden Clinic | Beamion LUNG-3: A randomized, controlled, multi-center trial evaluating zongertinib as an adjuvant monotherapy compared with standard of care in patients with early-stage, resectable non-small cell lung cancer (Stage II-IIIB) harboring tyrosine kinase domain activating HER2 mutations | No dispute reported | 06/30/2026 | 1220696165 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $14,500.00 | 11/19/2025 | Non-covered Recipient Entity Community Cancer Trials Of Utah | Beamion LUNG-3: A randomized, controlled, multi-center trial evaluating zongertinib as an adjuvant monotherapy compared with standard of care in patients with early-stage, resectable non-small cell lung cancer (Stage II-IIIB) harboring tyrosine kinase domain activating HER2 mutations | No dispute reported | 06/30/2026 | 1220799147 |
| Principal investigator 1 | Amgen Inc. | $420.57 | 11/10/2025 | Non-covered Recipient Entity UT HEMA OCONCOMM | PROCLAIM: A Phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatment of Chemotherapy-induced Thrombocytopenia in Patients Receiving Chemotherapy for Treatment of Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer | No dispute reported | 06/30/2026 | 1246651054 |
| Principal investigator 1 | Incyte Corporation | $266.40 | 11/10/2025 | Non-covered Recipient Entity COMMUNITY CANCER TRIALS OF UTAH | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind | No dispute reported | 06/30/2026 | 1240519678 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $244.49 | 10/23/2025 | Non-covered Recipient Entity COMMUNITY CANCER TRIALS OF UTAH LLC | A PHASE 3, OPEN LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN COMBINATION WITH CHOP (O-CHOP) VERSUS RITUXIMAB IN COMBINATION WITH CHOP (R-CHOP) IN PREVIOUSLY UNTREATED PARTICIPANTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) (OLYMPIA-3) | No dispute reported | 06/30/2026 | 1184252620 |
| Recipient | Eli Lilly and Company | $716.53 | 10/20/2025 | Covered Recipient Physician | A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE LY3537021 FOR THE TREATMENT OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING IN ADULT PARTICIPANTS WITH MALIGNANT DISEASE | No dispute reported | 06/30/2026 | 1187871121 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,066.04 | 10/16/2025 | Non-covered Recipient Entity COMMUNITY CANCER TRIALS OF UTAH LLC | A PHASE 3, OPEN LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN COMBINATION WITH CHOP (O-CHOP) VERSUS RITUXIMAB IN COMBINATION WITH CHOP (R-CHOP) IN PREVIOUSLY UNTREATED PARTICIPANTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) (OLYMPIA-3) | No dispute reported | 06/30/2026 | 1184250599 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,097.35 | 10/09/2025 | Non-covered Recipient Entity COMMUNITY CANCER TRIALS OF UTAH LLC | A PHASE 3, OPEN LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN COMBINATION WITH CHOP (O-CHOP) VERSUS RITUXIMAB IN COMBINATION WITH CHOP (R-CHOP) IN PREVIOUSLY UNTREATED PARTICIPANTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) (OLYMPIA-3) | No dispute reported | 06/30/2026 | 1184248958 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $11,250.00 | 10/09/2025 | Non-covered Recipient Entity Community Cancer Trials Of Utah, Llc | Evaluate the efficacy and safety of oral rilzabrutinib as frontline treatment in adults diagnosed with primary ITP | No dispute reported | 06/30/2026 | 1226131684 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,249.00 | 10/06/2025 | Non-covered Recipient Entity COMMUNITY CANCER TRIALS OF UTAH LLC | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1175415431 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $785.00 | 10/01/2025 | Non-covered Recipient Entity Utah Hematology Oncology Ogden Clinic | Beamion LUNG-3: A randomized, controlled, multi-center trial evaluating zongertinib as an adjuvant monotherapy compared with standard of care in patients with early-stage, resectable non-small cell lung cancer (Stage II-IIIB) harboring tyrosine kinase domain activating HER2 mutations | No dispute reported | 06/30/2026 | 1220696151 |
| Principal investigator 1 | ABBVIE INC. | $14,500.00 | 09/04/2025 | Non-covered Recipient Entity COMMUNITY CANCER TRIALS OF UTAH | A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1202509992 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,358.00 | 09/01/2025 | Non-covered Recipient Entity COMMUNITY CANCER TRIALS OF UTAH LLC | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1175415400 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,809.30 | 08/21/2025 | Non-covered Recipient Entity COMMUNITY CANCER TRIALS OF UTAH LLC | A PHASE 3, OPEN LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN COMBINATION WITH CHOP (O-CHOP) VERSUS RITUXIMAB IN COMBINATION WITH CHOP (R-CHOP) IN PREVIOUSLY UNTREATED PARTICIPANTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) (OLYMPIA-3) | No dispute reported | 06/30/2026 | 1184229743 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,496.70 | 08/21/2025 | Non-covered Recipient Entity COMMUNITY CANCER TRIALS OF UTAH LLC | A PHASE 3, OPEN LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN COMBINATION WITH CHOP (O-CHOP) VERSUS RITUXIMAB IN COMBINATION WITH CHOP (R-CHOP) IN PREVIOUSLY UNTREATED PARTICIPANTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) (OLYMPIA-3) | No dispute reported | 06/30/2026 | 1184229745 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $265.74 | 08/07/2025 | Non-covered Recipient Entity COMMUNITY CANCER TRIALS OF UTAH LLC | A PHASE 3, OPEN LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN COMBINATION WITH CHOP (O-CHOP) VERSUS RITUXIMAB IN COMBINATION WITH CHOP (R-CHOP) IN PREVIOUSLY UNTREATED PARTICIPANTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) (OLYMPIA-3) | No dispute reported | 06/30/2026 | 1184226137 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,720.00 | 08/04/2025 | Non-covered Recipient Entity COMMUNITY CANCER TRIALS OF UTAH LLC | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1175415446 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,000.00 | 07/31/2025 | Non-covered Recipient Entity COMMUNITY CANCER TRIALS OF UTAH LLC | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20X ANTI-CD3 BISPECIFIC ANTIBODY, COMBINED WITH CHEMOTHERAPY VERSUS RITUXIMAB COMBINED WITH CHEMOTHERAPY IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-2) | No dispute reported | 06/30/2026 | 1184222834 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,095.00 | 07/25/2025 | Non-covered Recipient Entity COMMUNITY CANCER TRIALS OF UTAH LLC | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1175415334 |
| Principal investigator 1 | Janssen Research & Development, LLC | $20,975.00 | 07/25/2025 | Non-covered Recipient Entity COMMUNITY CANCER TRIALS OF UTAH LLC | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1175415366 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,000.00 | 07/25/2025 | Non-covered Recipient Entity COMMUNITY CANCER TRIALS OF UTAH LLC | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1175415420 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $265.74 | 07/17/2025 | Non-covered Recipient Entity COMMUNITY CANCER TRIALS OF UTAH LLC | A PHASE 3, OPEN LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN COMBINATION WITH CHOP (O-CHOP) VERSUS RITUXIMAB IN COMBINATION WITH CHOP (R-CHOP) IN PREVIOUSLY UNTREATED PARTICIPANTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) (OLYMPIA-3) | No dispute reported | 06/30/2026 | 1184217068 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $10,356.46 | 07/04/2025 | Non-covered Recipient Entity COMMUNITY CANCER TRIALS OF UTAH LLC | A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA | No dispute reported | 06/30/2026 | 1192112280 |
| Principal investigator 1 | Janssen Research & Development, LLC | $40,903.00 | 07/04/2025 | Non-covered Recipient Entity COMMUNITY CANCER TRIALS OF UTAH LLC | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1175415348 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,974.40 | 07/04/2025 | Non-covered Recipient Entity COMMUNITY CANCER TRIALS OF UTAH LLC | A PHASE 3, OPEN LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN COMBINATION WITH CHOP (O-CHOP) VERSUS RITUXIMAB IN COMBINATION WITH CHOP (R-CHOP) IN PREVIOUSLY UNTREATED PARTICIPANTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) (OLYMPIA-3) | No dispute reported | 06/30/2026 | 1184212867 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,482.90 | 06/19/2025 | Non-covered Recipient Entity COMMUNITY CANCER TRIALS OF UTAH LLC | A PHASE 3, OPEN LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN COMBINATION WITH CHOP (O-CHOP) VERSUS RITUXIMAB IN COMBINATION WITH CHOP (R-CHOP) IN PREVIOUSLY UNTREATED PARTICIPANTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) (OLYMPIA-3) | No dispute reported | 06/30/2026 | 1184209183 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $265.74 | 06/19/2025 | Non-covered Recipient Entity COMMUNITY CANCER TRIALS OF UTAH LLC | A PHASE 3, OPEN LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN COMBINATION WITH CHOP (O-CHOP) VERSUS RITUXIMAB IN COMBINATION WITH CHOP (R-CHOP) IN PREVIOUSLY UNTREATED PARTICIPANTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) (OLYMPIA-3) | No dispute reported | 06/30/2026 | 1184209185 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $265.74 | 06/19/2025 | Non-covered Recipient Entity COMMUNITY CANCER TRIALS OF UTAH LLC | A PHASE 3, OPEN LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN COMBINATION WITH CHOP (O-CHOP) VERSUS RITUXIMAB IN COMBINATION WITH CHOP (R-CHOP) IN PREVIOUSLY UNTREATED PARTICIPANTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) (OLYMPIA-3) | No dispute reported | 06/30/2026 | 1184209187 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $500.00 | 06/19/2025 | Non-covered Recipient Entity COMMUNITY CANCER TRIALS OF UTAH LLC | A PHASE 3, OPEN LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN COMBINATION WITH CHOP (O-CHOP) VERSUS RITUXIMAB IN COMBINATION WITH CHOP (R-CHOP) IN PREVIOUSLY UNTREATED PARTICIPANTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) (OLYMPIA-3) | No dispute reported | 06/30/2026 | 1184209189 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,984.78 | 06/19/2025 | Non-covered Recipient Entity COMMUNITY CANCER TRIALS OF UTAH LLC | A PHASE 3, OPEN LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN COMBINATION WITH CHOP (O-CHOP) VERSUS RITUXIMAB IN COMBINATION WITH CHOP (R-CHOP) IN PREVIOUSLY UNTREATED PARTICIPANTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) (OLYMPIA-3) | No dispute reported | 06/30/2026 | 1184209191 |
| Principal investigator 1 | Incyte Corporation | $1,000.00 | 06/03/2025 | Non-covered Recipient Entity COMMUNITY CANCER TRIALS OF UTAH | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind | No dispute reported | 06/30/2026 | 1240519672 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,846.00 | 05/26/2025 | Non-covered Recipient Entity COMMUNITY CANCER TRIALS OF UTAH LLC | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1175415411 |
| Principal investigator 1 | ABBVIE INC. | $3,500.00 | 05/15/2025 | Non-covered Recipient Entity COMMUNITY CANCER TRIALS OF UTAH | A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1202484999 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,819.00 | 05/05/2025 | Non-covered Recipient Entity COMMUNITY CANCER TRIALS OF UTAH LLC | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1175415386 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $1,613.10 | 04/30/2025 | Non-covered Recipient Entity AGA CLINICAL TRIALS | A Phase 3 Open-label Trial of Neoadjuvant Trastuzumab Deruxtecan (T-DXd) Monotherapy or T-DXd followed by THP Compared to ddAC-THP in Participants with High-risk HER2-positive Early-stage Breast Cancer (DESTINY-Breast11) | No dispute reported | 06/30/2026 | 1185540331 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,260.00 | 04/22/2025 | Non-covered Recipient Entity COMMUNITY CANCER TRIALS OF UTAH LLC | A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA | No dispute reported | 06/30/2026 | 1192112288 |
| Principal investigator 1 | Incyte Corporation | $1,274.33 | 04/15/2025 | Non-covered Recipient Entity COMMUNITY CANCER TRIALS OF UTAH | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind | No dispute reported | 06/30/2026 | 1240519669 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,195.00 | 04/07/2025 | Non-covered Recipient Entity COMMUNITY CANCER TRIALS OF UTAH LLC | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1175415380 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,281.00 | 04/07/2025 | Non-covered Recipient Entity COMMUNITY CANCER TRIALS OF UTAH LLC | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1175415416 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,420.00 | 03/31/2025 | Non-covered Recipient Entity COMMUNITY CANCER TRIALS OF UTAH LLC | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1175415441 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,195.00 | 03/14/2025 | Non-covered Recipient Entity COMMUNITY CANCER TRIALS OF UTAH LLC | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1175415404 |
| Principal investigator 1 | Janssen Research & Development, LLC | $17,772.00 | 03/10/2025 | Non-covered Recipient Entity COMMUNITY CANCER TRIALS OF UTAH LLC | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1175415360 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $2,614.20 | 03/10/2025 | Non-covered Recipient Entity COMMUNITY CANCER TRIALS OF UTAH, LLC | A Phase III, Randomized, Double-blind Study of Ianalumab (VAY736) Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (VAYHIT1) | No dispute reported | 06/30/2026 | 1190309590 |
| Principal investigator 1 | ABBVIE INC. | $2,025.00 | 03/05/2025 | Non-covered Recipient Entity COMMUNITY CANCER TRIALS OF UTAH | M18-868 - A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1202455862 |
| Principal investigator 1 | Amgen Inc. | $115,906.22 | 02/22/2025 | Non-covered Recipient Entity COMMUNITY CANCER TRIALS OF UTAH | PROCLAIM: A Phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatment of Chemotherapy-induced Thrombocytopenia in Patients Receiving Chemotherapy for Treatment of Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer | No dispute reported | 06/30/2026 | 1246640465 |
| Principal investigator 1 | AstraZeneca UK Limited | $152,771.40 | 02/12/2025 | Non-covered Recipient Entity COMMUNITY CANCER TRIALS OF UTAH, LLC | CAMBRIA-1 A Phase III, Open-Label,Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2 | No dispute reported | 06/30/2026 | 1185540335 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,195.00 | 02/10/2025 | Non-covered Recipient Entity COMMUNITY CANCER TRIALS OF UTAH LLC | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1175415356 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,000.00 | 02/10/2025 | Non-covered Recipient Entity COMMUNITY CANCER TRIALS OF UTAH LLC | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1175415392 |
| Principal investigator 1 | ABBVIE INC. | $14,500.00 | 02/06/2025 | Non-covered Recipient Entity COMMUNITY CANCER TRIALS OF UTAH | M22-128 - A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (EPCORE DLBCL-4) | No dispute reported | 06/30/2026 | 1202448129 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,716.00 | 02/03/2025 | Non-covered Recipient Entity COMMUNITY CANCER TRIALS OF UTAH LLC | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1175415343 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $13,004.60 | 01/24/2025 | Non-covered Recipient Entity COMMUNITY CANCER TRIALS OF UTAH, LLC | A Phase 3 Open-label Trial of Neoadjuvant Trastuzumab Deruxtecan (T-DXd) Monotherapy or T-DXd followed by THP Compared to ddAC-THP in Participants with High-risk HER2-positive Early-stage Breast Cancer (DESTINY-Breast11) | No dispute reported | 06/30/2026 | 1185540333 |
| Principal investigator 1 | Incyte Corporation | $57,893.76 | 01/14/2025 | Non-covered Recipient Entity COMMUNITY CANCER TRIALS OF UTAH | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind | No dispute reported | 06/30/2026 | 1240519665 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $5,393.41 | 01/01/2025 | Non-covered Recipient Entity COMMUNITY CANCER TRIALS OF UTAH, LLC | A Phase II Multicenter, Open-label, Single-arm Dose Escalation Study of Asciminib Monotherapy in 2nd Line Chronic Phase - Chronic Myelogenous Leukemia | No dispute reported | 06/30/2026 | 1190309588 |